These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38216673)

  • 1. IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion.
    Xu B; Sun H; Liu S; Liao L; Song X; Wu Y; Hou Y; Jin W
    Oncogene; 2024 Mar; 43(10):693-702. PubMed ID: 38216673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
    Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
    Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.
    Wu SY; Xiao Y; Wei JL; Xu XE; Jin X; Hu X; Li DQ; Jiang YZ; Shao ZM
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.
    Wang X; Feng M; Xiao T; Guo B; Liu D; Liu C; Pei J; Liu Q; Xiao Y; Rosin-Arbesfeld R; Shi Y; Zhou Y; Yang M; Feng YX; Jiang Y; Shao Z; Yu K; Zhu D
    Oncogene; 2021 Apr; 40(16):2982-2997. PubMed ID: 33767438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer.
    Yan Z; Zhong Z; Shi C; Feng M; Feng X; Liu T
    Cancer Biol Ther; 2024 Dec; 25(1):2355705. PubMed ID: 38778753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
    Gao M; Wang T; Ji L; Bai S; Tian L; Song H
    Front Immunol; 2020; 11():366. PubMed ID: 32194569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
    Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
    Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the Tumor Microenvironment in TNBC and Deep Exploration for M1 Macrophages-Associated Prognostic Genes.
    Xu B; Sun H; Song X; Liu Q; Jin W
    Front Immunol; 2022; 13():923481. PubMed ID: 35844580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
    Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
    Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-secreted IFI35 promotes proliferation and cytotoxic activity of CD8
    Li P; Zhou D; Chen D; Cheng Y; Chen Y; Lin Z; Zhang X; Huang Z; Cai J; Huang W; Lin Y; Ke H; Long J; Zou Y; Ye S; Lan P
    J Biomed Sci; 2023 Jun; 30(1):47. PubMed ID: 37380972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
    Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
    Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
    JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological spatial analysis on the induction of PD-L1
    Suzuki K; Ohe R; Kabasawa T; Kitaoka T; Kawai M; Motoi F; Futakuchi M
    Breast Cancer; 2023 Nov; 30(6):1094-1104. PubMed ID: 37792212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of inflammatory infiltrates in triple negative breast cancer.
    Matsumoto H; Koo SL; Dent R; Tan PH; Iqbal J
    J Clin Pathol; 2015 Jul; 68(7):506-10. PubMed ID: 25750267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
    Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
    Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors.
    Suryawanashi YR; Zhang T; Woyczesczyk HM; Christie J; Byers E; Kohler S; Eversole R; Mackenzie C; Essani K
    Med Oncol; 2017 Jun; 34(6):112. PubMed ID: 28466296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.